These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35562800)

  • 1. Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma.
    Feng W; Lin A; Sun L; Wei T; Ying H; Zhang J; Luo P; Zhu W
    Cancer Cell Int; 2022 May; 22(1):186. PubMed ID: 35562800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.
    Zhou C; Lin A; Cao M; Ding W; Mou W; Guo N; Chen Z; Zhang J; Luo P
    Front Immunol; 2021; 12():634741. PubMed ID: 34220801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma.
    Hong S; Zhang Y; Cao M; Lin A; Yang Q; Zhang J; Luo P; Guo L
    Front Cell Dev Biol; 2021; 9():762478. PubMed ID: 34901008
    [No Abstract]   [Full Text] [Related]  

  • 4. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma.
    Lin A; Xu W; Luo P; Zhang J
    Front Pharmacol; 2021; 12():721181. PubMed ID: 34721019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
    Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A
    Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Chen S; Zhang N; Wang T; Zhang E; Wang X; Zheng J
    Front Immunol; 2020; 11():1900. PubMed ID: 32983112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell atlases link macrophages and CD8
    Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
    Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy.
    Hassler MR; Moedlagl V; Hindinger H; Krauter J; Klager S; Resch I; Huebner N; Yurdakul O; Ofner H; Korn SM; D'Andrea D; Gust K; Shariat SF
    Eur Urol Focus; 2023 Dec; ():. PubMed ID: 38161107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
    Lin A; Gu T; Hu X; Zhang J; Luo P
    J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Sun Y; Yang Q; Shen J; Wei T; Shen W; Zhang N; Luo P; Zhang J
    Front Cell Dev Biol; 2021; 9():745859. PubMed ID: 34660603
    [No Abstract]   [Full Text] [Related]  

  • 15. Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma.
    Zhang Y; Li X; Zhou R; Lin A; Cao M; Lyu Q; Luo P; Zhang J
    Front Pharmacol; 2021; 12():723066. PubMed ID: 34512351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer.
    Gong Z; He Y; Mi X; Li C; Sun X; Wang G; Li L; Han Y; Xu C; Wang W; Cai S; Wang L; Liu Z
    Aging (Albany NY); 2023 Sep; 15(18):9479-9498. PubMed ID: 37747262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer.
    Lin A; Yao J; Cheng Q; Liu Z; Luo P; Zhang J
    J Inflamm Res; 2023; 16():1693-1709. PubMed ID: 37092128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
    Wang Z; Wang C; Lin S; Yu X
    Front Oncol; 2021; 11():725292. PubMed ID: 34513703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.